Panacea Biotec — Peer Comparison

How the peer fair value is calculated and which companies were used as benchmarks.

Peer selection

Peers are selected from the same Healthcare industry. 8 companies were matched as valid comparables.

Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.

Peer comparison table

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Panacea Biotec PANACEABIO · you	₹2,304 Cr	56.1×	2.9×	—	-0.6%	-0.8%	11.6%
Sector median	—	43.0×	6.6×	21.3×	12.6%	3.2%	10.2%
Dr. Agarwal's Health Care Limited AGARWALEYE	₹16,045 Cr	349.0×	—	—	—	0.0%	—
Alembic Pharmaceuticals Limited APLLTD	₹15,334 Cr	24.2×	2.9×	15.6×	11.9%	9.2%	9.1%
Park Medi World Limited PARKHOSPS	₹12,549 Cr	40.9×	6.0×	27.2×	12.8%	15.4%	10.2%
Akums Drugs and Pharmaceuticals Limited AKUMS	₹12,161 Cr	45.1×	3.5×	20.9×	7.7%	5.9%	6.0%
Thyrocare Technologies Limited THYROCARE	₹9,929 Cr	60.9×	20.7×	—	34.0%	0.2%	—
Jupiter Life Line Hospitals Limited JLHL	₹9,880 Cr	53.4×	6.7×	29.1×	12.6%	12.9%	18.9%
Procter & Gamble Health Limited PGHL	₹9,850 Cr	27.6×	16.1×	—	58.5%	0.3%	—
Healthcare Global Enterprises Limited HCG	₹8,780 Cr	638.1×	6.6×	21.3×	1.0%	0.5%	14.5%

Peer comparison verdict

Panacea trades at a premium to sector peers on P/E (56.1× vs median 43.0×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.

Why median? Why these weights?

Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.

Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.

Limitations of peer comparison

Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.

The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.